The minister has warned that without reform, the NDIS would cost more than Medicare and the PBS combined by the end of the decade. On some measures, it already does. Once rebates are deducted from the PBS, total NDIS spending of about $51 billion last financial year edged past the roughly $50 billion spent on Medicare and the PBS together.
-
Latest News
Government turns again to cheaper medicines as Guild eyes co-payment freeze
The Albanese government is again expected to put cheaper medicines at the centre of its cost-of-living message. That could deliver the outcome the Pharmacy Guild of Australia has spent three months campaigning for.
-
Latest News A tale of two government programs - one held flat and the other still running hot November 19, 2026
-
Latest News Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda November 19, 2026Moderna will seek National Immunisation Program listings for two mRNA vaccines at the Pharmaceutical Benefits Advisory Committee's March 2027 meeting. The agenda includes 31 major submissions and resubmissions, 8 minor submissions, and 4 utilisation reviews. Consumer comments close on 20 January 2027.
-
New Zealand risks losing $763 million clinical trials sector as other countries step up November 19, 2026Clinical trials added $763 million to New Zealand's economy in 2025, but that contribution is at risk as other countries compete more aggressively for global trial investment, according to a new report from the New Zealand Institute of Economic Research.
-
Lilly's Foundayo joins Novo Nordisk's Wegovy pill as oral GLP-1s reach Australia November 18, 2026Lilly Australia General Manager Dr Manny Simons said FOUNDAYO resulted from more than a decade of research. "FOUNDAYO clinical trials involved more than 10,000 patients in 15 countries, including partnerships with a dozen Australian hospitals and clinics," he said.
-
Latest News The TGA's new guidance risks blurring the line between advertising and journalism November 18, 2026Will Collie of The Advisory Ward argues that the Therapeutic Goods Administration might be right to target disguised pharmaceutical promotion, but its new guidance risks blurring the line between where information comes from and whether the journalism built on it is independent.
-
Latest News Hungary's Gedeon Richter offers $604 million for Mayne Pharma November 18, 2026The Australian company traces its roots to F.H. Faulding & Co., which began as a pharmacy that Francis Hardey Faulding opened on Rundle Street in Adelaide in 1845.
-
Latest News Ipsen marks 25 years in Australia as rare disease listings broaden patient access November 17, 2026Ipsen has marked 25 years of Australian operations with a celebration at its South Yarra headquarters in Melbourne. The event recognised the staff, clinicians and patient advocates who have worked with the company to bring new treatments to Australian patients.
-
Latest News Canberra discovers what it really feels like to face a single buyer, and the response is hypocrisy November 17, 2026Beijing created the PBS-style CMRG in 2022 to pool the buying power of China's steel mills, and it now handles more than 80 per cent of the country's iron ore procurement. Goldman Sachs estimates China will save close to US$10 billion over the next decade. That is money that would otherwise flow to Australian miners and the federal budget. The Australian response has been telling. Hypocrisy.
-
Latest News US biotech lobby's call for a White House strategy echoes AusBiotech push November 17, 2026BIO has asked Washington for a coordinated national biotech strategy to counter China, while AusBiotech is still pressing Canberra for Australia's first whole-of-government life sciences strategy and council.
-
Third global honour of 2026 for cochlear implant pioneer Graeme Clark November 17, 2026Professor Clark is only the second Australian to receive the Honda Prize since the Honda Foundation established it in 1980. The first was Professor Ian Frazer, honoured in 2009 for his work on cervical cancer vaccines.
-
Latest News Can the PBS afford another agreement on the same terms? November 16, 2026Agreements of this kind have been a fixture of the PBS since 2010. Before the talks for new agreements begin, it is worth asking whether this round can break a pattern that has undoubtedly harmed one of the country's most important public health programs. Since 2010, the PBS has been unquestionably less able to deliver on its core purpose.
-
Latest News First official US count confirms the broad uptake of GLP-1s for weight management November 16, 2026What sets the US apart is not only the level of use but the fact that its government has measured it. The CDC estimate gives American policymakers an official picture of who is using the medicines and why. Australia, Canada and the UK rely on commercial data, academic surveys and polling, and in Australia weight-loss use runs entirely through private prescriptions that fall outside PBS data.
-
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits November 16, 2026Medicines Australia told a federal parliamentary inquiry that the rules used to assess medicines for PBS reimbursement exclude many of the economic benefits of new treatments, limiting both patient access and national productivity.
-
Podcast The 'Dispatched' Week in Review Podcast - 13 November November 13, 2026We look back on Monday's AI summit, including Matt Little's presentation on AI in advocacy and a patient panel of people living with pancreatic cancer. The health system is built for delay, not access, and seriously ill patients cannot wait years for HTA reform. Long tenures on advisory committees have bred groupthink. The government's rush to keep AI and the core elements of HTA reform out of agreement negotiations shows an institution resisting change it cannot outrun. It might signal pending institutional failure.
-
Latest News A year on, Sanofi now asks staff to explain how they used AI November 13, 2026Country lead and head of pharma Liz Selby and head of corporate affairs Luke Cornish returned to the summit a year after their first appearance, this time joined by country regulatory head Samantha Howell, to describe a company where AI use is now assumed.
-
There is no need for AI to automate the care out of healthcare, Cohn warns November 13, 2026Artificial intelligence will either rehumanise healthcare or industrialise it, and the technology will not make that choice, Aurelia Cohn told the AI Health Summit.
-
Latest News Cochlear's global government affairs chief is putting AI to work November 13, 2026Contesting everything, he explained, would have left Cochlear in Washington defending positions that cut across the Australian government's case rather than its own. "It'll be insightful, but it's not always going to be right," he said of AI.
-
Latest News Longevity Life Sciences welcomes longer TGA exclusivity and calls for existing ingredients to be included November 13, 2026Sally Panton, the company's cofounder and chief executive, said she hoped the decision would be the first of several reforms supporting the sector, including recognition of innovators already in the system.
-
Latest News Patients tired of polite nods turning to AI to force Canberra's hand November 12, 2026Danielle Ozolins was 48 when she was diagnosed with pancreatic cancer. Within 10 days, she underwent a Whipple procedure, followed by chemotherapy that her doctors warned would be a sledgehammer. At her first scan afterwards, she learned the cancer had spread to her lungs. She was told nothing more could be done and given nine to 12 months to live.
-
Latest News Institutions cannot outrun the disruptive impact of technological change forever November 12, 2026Our health technology assessment decision-makers would not be the first institution to respond to technological disruption by tightening control. Nor would they be the first to discover how that ends.
Australian Biotech
-
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 -
US biotech lobby's call for a White House strategy echoes AusBiotech push
November 17, 2026 -
Cartherics takes ovarian cancer cell therapy to London as first human trial nears
November 11, 2026 -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026
Other Health
-
Edwards Lifesciences opens new Sydney head office as heart valve disease burden grows
November 1, 2026 -
Families take the fight for faster juvenile arthritis diagnosis to Parliament House
October 13, 2026 -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 -
Bupa to discontinue international referrals for 'Doctors on Demand' telehealth
September 7, 2026 -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026
Latest Video
New Stories
-
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

